|
57 Products |
| 57 Products |
|
190 Diseases |  |
11246 News |  |
| «12...9596979899100101102103104105...109110» |
- ||| Mayzent (siponimod) / Novartis
Trial termination: Safety and Efficacy of BAF312 in Dermatomyositis (clinicaltrials.gov) - Jan 15, 2019
P2, N=17, Terminated, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; The study was terminated prematurely after an interim analysis for futility. The study did not provide any evidence for efficacy of BAF312 in dermatomyositis.
- | glatiramer acetate / Generic mfg., fingolimod / Generic mfg.
Trial primary completion date, HEOR, Patient reported outcomes: Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate (clinicaltrials.gov) - Jan 15, 2019
P=N/A, N=157, Active, not recruiting, Sponsor: University of Colorado, Denver
The study did not provide any evidence for efficacy of BAF312 in dermatomyositis. Trial primary completion date: Dec 2018 --> Mar 2019
- | BXQ-350 / Bexion
Trial completion date, Trial primary completion date, Metastases: Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 10, 2019
P1, N=40, Recruiting, Sponsor: Bexion Pharmaceuticals, LLC.
Trial primary completion date: Dec 2018 --> Mar 2019 Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Oct 2018 --> Nov 2019
- || OPL-0301 / Valo Health
Trial completion, Enrollment change: Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jan 9, 2019
P1, N=23, Completed, Sponsor: Sanofi
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Oct 2018 --> Nov 2019 Recruiting --> Completed | N=108 --> 23
- | fingolimod / Generic mfg.
Trial completion date, Trial primary completion date: FINGORHYMS: Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 8, 2019
P=N/A, N=100, Recruiting, Sponsor: Universit
Recruiting --> Completed | N=108 --> 23 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- ||||| Zeposia (ozanimod) / BMS
Enrollment closed: DAYBREAK: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jan 3, 2019
P3, N=2495, Active, not recruiting, Sponsor: Celgene
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Enrolling by invitation --> Active, not recruiting
- || cenerimod (ACT-334441) / Idorsia
Trial completion date, Trial primary completion date: CARE: Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus (clinicaltrials.gov) - Dec 24, 2018
P2b, N=500, Not yet recruiting, Sponsor: Idorsia Pharmaceuticals Ltd.
Enrolling by invitation --> Active, not recruiting Trial completion date: Jun 2019 --> Sep 2021 | Trial primary completion date: Jun 2019 --> May 2021
- || Veyonda (idronoxil) / Noxopharm
New P1 trial: A Study of Safety and Tolerability of NOX66 in Healthy Volunteers (clinicaltrials.gov) - Dec 19, 2018
P1, N=50, Not yet recruiting, Sponsor: Noxopharm Limited
- | Zeposia (ozanimod) / BMS
Trial completion date: TOUCHSTONE: Efficacy and Safety Study of Ozanimod in Ulcerative Colitis (clinicaltrials.gov) - Dec 11, 2018
P2, N=197, Active, not recruiting, Sponsor: Celgene
Trial completion date: Jun 2019 --> Sep 2021 | Trial primary completion date: Jun 2019 --> May 2021 Trial completion date: Dec 2019 --> Jul 2019
- ||||||| fingolimod / Generic mfg.
Trial completion: Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Dec 6, 2018
P3, N=4125, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2019 --> Jul 2019 Active, not recruiting --> Completed
- | Veyonda (idronoxil) / Noxopharm
Trial completion date, Trial primary completion date, Combination therapy: Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer (clinicaltrials.gov) - Dec 5, 2018
P1b, N=24, Recruiting, Sponsor: Noxopharm Limited
Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Dec 2019
- |||||| Zeposia (ozanimod) / BMS
Enrollment open: An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Dec 3, 2018
P3, N=1200, Recruiting, Sponsor: Celgene
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- | fingolimod / Generic mfg.
Enrollment change, Trial termination: Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod (clinicaltrials.gov) - Nov 29, 2018
P=N/A, N=21, Terminated, Sponsor: Charite University, Berlin, Germany
Not yet recruiting --> Recruiting N=40 --> 21 | Active, not recruiting --> Terminated
- | New P1 trial: Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of Fingolimod (clinicaltrials.gov) - Nov 27, 2018
P1, N=33, Completed, Sponsor: Asofarma S.A.I. y C.
- | Zeposia (ozanimod) / BMS
Enrollment open: A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Nov 16, 2018
P3, N=485, Recruiting, Sponsor: Celgene
N=40 --> 21 | Active, not recruiting --> Terminated Not yet recruiting --> Recruiting
- | Velsipity (etrasimod) / Pfizer
Trial completion date, Trial primary completion date: Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis (clinicaltrials.gov) - Nov 15, 2018
P2, N=20, Recruiting, Sponsor: Arena Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | cenerimod (ACT-334441) / Idorsia
New P2b trial: CARE: Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 15, 2018
P2b, N=500, Not yet recruiting, Sponsor: Idorsia Pharmaceuticals Ltd.
- | mocravimod (KRP-203) / Priothera
Trial completion: A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies (clinicaltrials.gov) - Nov 7, 2018
P1, N=23, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- | Zeposia (ozanimod) / BMS
Enrollment open: Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites (clinicaltrials.gov) - Nov 7, 2018
P=N/A, N=230, Recruiting, Sponsor: Celgene
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | fingolimod / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Gilenya's Impact on Cognitive Function and Thalamic Volumes (clinicaltrials.gov) - Nov 2, 2018
P=N/A, N=20, Active, not recruiting, Sponsor: The Cleveland Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Oct 2019
- | fingolimod / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (clinicaltrials.gov) - Nov 1, 2018
P=N/A, N=135, Completed, Sponsor: McGill University
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Oct 2019 Active, not recruiting --> Completed | N=100 --> 135 | Trial completion date: Feb 2018 --> Oct 2018
- | Veyonda (idronoxil) / Noxopharm
Trial completion date, Trial primary completion date, Metastases: Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 31, 2018
P1, N=12, Recruiting, Sponsor: Royal North Shore Hospital
Active, not recruiting --> Completed | N=100 --> 135 | Trial completion date: Feb 2018 --> Oct 2018 Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | Velsipity (etrasimod) / Pfizer
Trial completion date, Trial termination, Trial primary completion date: Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum (clinicaltrials.gov) - Oct 18, 2018
P2a, N=2, Terminated, Sponsor: Arena Pharmaceuticals
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Trial completion date: Dec 2017 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> May 2018; Terminated [Sponsor decision to terminate the study]
- | Trial completion, Enrollment change: Efficacy and Safety of FTY720 for Acute Stroke (clinicaltrials.gov) - Oct 17, 2018
P2, N=22, Completed, Sponsor: Tianjin Medical University General Hospital
Trial completion date: Dec 2017 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> May 2018; Terminated [Sponsor decision to terminate the study] Recruiting --> Completed | N=87 --> 22
- | Velsipity (etrasimod) / Pfizer
Trial completion: OASIS: Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis (clinicaltrials.gov) - Oct 17, 2018
P2, N=156, Completed, Sponsor: Arena Pharmaceuticals
Recruiting --> Completed | N=87 --> 22 Active, not recruiting --> Completed
- | glatiramer acetate / Generic mfg., fingolimod / Generic mfg.
Trial completion date, Trial primary completion date, HEOR, Patient reported outcomes: Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=157, Active, not recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Dec 2018
- | Zeposia (ozanimod) / BMS
New P1 trial: Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response (clinicaltrials.gov) - Oct 2, 2018
P1, N=92, Recruiting, Sponsor: Celgene
- | fingolimod / Generic mfg.
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. (Pubmed Central) - Sep 23, 2018
P3
Longer studies are required to determine the durability and safety of fingolimod in pediatric multiple sclerosis. (Funded by Novartis Pharma; PARADIG MS ClinicalTrials.gov number, NCT01892722 .).
- | fingolimod / Generic mfg.
Trial primary completion date: Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Sep 12, 2018
P3, N=4125, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
(Funded by Novartis Pharma; PARADIG MS ClinicalTrials.gov number, NCT01892722 .). Trial primary completion date: Jun 2018 --> Sep 2018
- | Zeposia (ozanimod) / BMS
Enrollment open, Trial completion date: Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Sep 7, 2018
P3, N=600, Recruiting, Sponsor: Celgene
Trial primary completion date: Jun 2018 --> Sep 2018 Not yet recruiting --> Recruiting | Trial completion date: Mar 2020 --> Jul 2020
- | Zeposia (ozanimod) / BMS
Enrollment open, Trial completion date: Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Sep 6, 2018
P3, N=600, Recruiting, Sponsor: Celgene
Not yet recruiting --> Recruiting | Trial completion date: Mar 2020 --> Jul 2020 Not yet recruiting --> Recruiting | Trial completion date: Mar 2020 --> Jul 2020
- ||| Zeposia (ozanimod) / BMS
New P1 trial: Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate (clinicaltrials.gov) - Aug 22, 2018
P1, N=60, Recruiting, Sponsor: Celgene
- |||| Zeposia (ozanimod) / BMS
Trial completion date, Trial primary completion date: True North: Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Aug 22, 2018
P3, N=900, Recruiting, Sponsor: Celgene
Not yet recruiting --> Recruiting | Trial completion date: Mar 2020 --> Jul 2020 Trial completion date: Nov 2018 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Jul 2020
- |||| Zeposia (ozanimod) / BMS
Trial completion date, Trial primary completion date: An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Aug 22, 2018
P3, N=1200, Recruiting, Sponsor: Celgene
Trial completion date: Nov 2018 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Jul 2020 Trial completion date: Dec 2020 --> Mar 2022 | Trial primary completion date: Dec 2020 --> Mar 2022
- | fingolimod / Generic mfg.
Trial completion date, Trial primary completion date: The Gilenya Pregnancy Registry (clinicaltrials.gov) - Aug 14, 2018
P=N/A, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2020 --> Mar 2022 | Trial primary completion date: Dec 2020 --> Mar 2022 Trial completion date: Sep 2023 --> Dec 2030 | Trial primary completion date: Sep 2023 --> Jul 2030
- ||| Zeposia (ozanimod) / BMS, avadomide (CC-122) / BMS
New P1 trial: Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A (clinicaltrials.gov) - Aug 10, 2018
P1, N=100, Recruiting, Sponsor: Celgene
- | Mayzent (siponimod) / Novartis
New P3 trial: EXCHANGE: Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients (clinicaltrials.gov) - Aug 8, 2018
P3, N=300, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Zeposia (ozanimod) / BMS
Trial completion date, Trial primary completion date: An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Jul 20, 2018
P3, N=1200, Recruiting, Sponsor: Celgene
Trial completion date: Sep 2023 --> Dec 2030 | Trial primary completion date: Sep 2023 --> Jul 2030 Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2020
- | cenerimod (ACT-334441) / Viatris
Enrollment change: Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 (clinicaltrials.gov) - Jul 10, 2018
P1, N=10, Terminated, Sponsor: Idorsia Pharmaceuticals Ltd.
Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2020 N=32 --> 10
- Trial completion, Trial completion date: FINGORETT: Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome (clinicaltrials.gov) - Jun 15, 2018
P1/2, N=6, Completed, Sponsor: University Hospital, Basel, Switzerland
N=32 --> 10 Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Apr 2018
- |||| Trial completion: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (clinicaltrials.gov) - Jun 7, 2018
P4, N=1064, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Apr 2018 Active, not recruiting --> Completed
- | Mavenclad (cladribine) / EMD Serono
New P4 trial: DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) - May 27, 2018
P4, N=800, Not yet recruiting, Sponsor: The Cleveland Clinic
- ||| Trial completion, Trial completion date, Trial primary completion date: Exploratory Study to Assess Clinical Response to Gilenya (clinicaltrials.gov) - May 3, 2018
P=N/A, N=51, Completed, Sponsor: University of Southern California
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Apr 2018 | Trial primary completion date: Jul 2017 --> Apr 2018
- | Mavenclad (cladribine) / EMD Serono
New trial: TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) - Apr 18, 2018
P=N/A, N=900, Recruiting, Sponsor: Johns Hopkins University
- |||| fingolimod / Generic mfg.
Trial primary completion date: PARADIGMS: Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Apr 17, 2018
P3, N=215, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Apr 2018 | Trial primary completion date: Jul 2017 --> Apr 2018 Trial primary completion date: Mar 2023 --> Jul 2017
- || Zeposia (ozanimod) / BMS
Phase classification: Radiance: Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (clinicaltrials.gov) - Apr 9, 2018
P2/3, N=1320, Completed, Sponsor: Celgene
Trial primary completion date: Mar 2023 --> Jul 2017 Phase classification: P3 --> P2/3
- || fingolimod / Generic mfg.
Phase classification: PASSAGE: Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (clinicaltrials.gov) - Apr 9, 2018
P, N=3620, Recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P3 --> P2/3 Phase classification: P=N/A --> P
- | Tysabri (natalizumab) / Biogen, Royalty, Rituxan (rituximab) / Roche, Lemtrada (alemtuzumab) / Sanofi
Phase classification: COMBAT-MS: COMparison Between All immunoTherapies for Multiple Sclerosis. (clinicaltrials.gov) - Apr 3, 2018
P, N=3700, Recruiting, Sponsor: Karolinska Institutet
Phase classification: P=N/A --> P Phase classification: P=N/A --> P
- |||| Mayzent (siponimod) / Novartis
Enrollment open: Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). (clinicaltrials.gov) - Apr 2, 2018
P2, N=100, Recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P=N/A --> P Not yet recruiting --> Recruiting
- |||| fingolimod / Generic mfg.
Trial primary completion date: Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Mar 30, 2018
P3, N=4125, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2018 --> Jun 2018